^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    avdoralimab (IPH5401)

    i
    Other names: IPH5401, NNC0215-0384, NN-8210, NNC-0215-0384, IPH 5401, anti-C5aR-215
    Associations

    News

    Trials
    Company:
    Innate, Novo Nordisk
    Drug class:
    C5aR inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost2years
    Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody (clinicaltrials.gov)
    P2, N=15, Completed, Centre Hospitalier Universitaire de Nice | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2024
    Trial completion • Trial completion date
    |
    avdoralimab (IPH5401)
    over3years
    IMMUNONCOVID: Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection (clinicaltrials.gov)
    P2, N=19, Completed, Centre Leon Berard | Active, not recruiting --> Completed | N=219 --> 19
    Trial completion • Enrollment change • Metastases
    |
    IL6 (Interleukin 6)
    |
    avdoralimab (IPH5401) • ezurpimtrostat (GNS561) • monalizumab (IPH2201)
    over4years
    IMMUNONCOVID: Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection (clinicaltrials.gov)
    P2, N=219, Active, not recruiting, Centre Leon Berard | Recruiting --> Active, not recruiting | Trial completion date: Aug 2021 --> Dec 2021
    Clinical • Enrollment closed • Trial completion date
    |
    IL6 (Interleukin 6)
    |
    avdoralimab (IPH5401) • ezurpimtrostat (GNS561) • monalizumab (IPH2201)